Diagnosis and management of thyroid carcinoma: A focus on serum thyroglobulin

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 1, 2009, Pages 25-43

  Grebe, Stefan K G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti thyroglobulin autoantibody; Assay interference; Assay sensitivity; Lymph node; Recombinant human thyrotropin; Thyroglobulin; Thyroid cancer incidence; Thyroid cancer prevalence; Thyroid neoplasm; Tumor marker; Tumor recurrence

Indexed keywords

HETEROPHILE ANTIBODY; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; TUMOR MARKER;

BODY FLUID; CANCER DIAGNOSIS; CANCER RECURRENCE; CYTOLOGY; DISEASE COURSE; ECHOGRAPHY; HUMAN; LYMPH NODE BIOPSY; MEASUREMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; REFERENCE VALUE; REVIEW; SENSITIVITY ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID HORMONE RELEASE; THYROID HORMONE SYNTHESIS; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

EID: 69949134873     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.4.1.25     Document Type: Review

References (136)

1. Ross DS. Nonpalpable thyroid nodules - managing an epidemic. J. Clin. Endocrinol. Metab. 87, 1938-1940 (2002).
2. Papini E, Guglielmi R, Bianchi A et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-doppler features. J. Clin. Endocrinol. Metab. 87, 1941-1946 (2002).
3. Mori I, Miyauchi A, Kuma S, Tang W, Kakudo K. Thyroid nodular lesion: analysis of cancer risk based on Kuma Hospital experience. Pathol. Int. 53, 579-583 (2003).
4. Kang HW, No JH, Chung JH et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14, 29-33(2004).
5. Frates MC, Benson CB, Doubulet PM et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J. Clin, Endocrinol. Metab. 91, 3411-34-17 (2006).
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin. 57, 43-66 (2007).
7. Silverberg E, Holleb AI. Cancer statistics 1974. CA Cancer J. Clin. 24, 2-21 (1974).
8. Silverberg E, Holleb AI. Cancer statistics 1975. CA Cancer J. Clin. 25, 8-21 (1975).
9. Seidman H, Silvbery E, Holleb AI. Cancer statistics 1976. CA Cancer J. Clin. 26, 14-29 (1976).
10. Silverberg E. Cancer statistics 1977. CA Cancer J. Clin. 27, 26-41 (1977).
11. Silverberg E. Cancer statistics 1978. CA Cancer J. Clin. 28, 17-32 (1978).
12. Silverberg E. Cancer statistics 1979. CA Cancer J. Clin. 29, 6-21 (1979).
13. Silverberg E. Cancer statistics 1980. CA Cancer J. Clin. 30, 23-38 (1980).
14. Silverberg E. Cancer statistics 1981. CA Cancer J. Clin. 31, 13-28 (1981).
15. Silverberg E. Cancer statistics 1982. CA Cancer J. Clin. 32, 15-31 (1982).
16. Silverberg E. Cancer statistics 1983. CA Cancer J. Clin. 33, 9-25 (1983).
17. Silverberg E. Cancer statistics 1984. CA Cancer J. Clin. 34, 7-23 (1984).
18. Silverberg E. Cancer statistics 1985. CA Cancer J. Clin. 35, 19-35 (1985).
19. Silverberg E. Cancer statistics 1986. CA Cancer J. Clin. 36, 9-25 (1986).
20. Silverberg E, Lubera J. Cancer statistics 1987. CA Cancer J. Clin. 37, 2-19 (1987).
21. Silverberg E, Lubera J. Cancer statistics 1988. CA Cancer J. Clin. 38, 5-22 (1988).
22. Silverberg E, Lubera J. Cancer statistics 1989. CA Cancer J. Clin. 39, 3-20 (1989).
23. Silverberg E, Boring CC, Squires TS. Cancer statistics 1990. CA Cancer J. Clin. 40, 9-26 (1990).
24. Boring CC, Squires TS, Tong T. Cancer statistics 1991. CA Cancer J. Clin. 41, 19-36 (1991).
25. Boring CC, Squires TS, Tong T. Cancer statistics 1992. CA Cancer J. Clin. 42, 19-38 (1992).
26. Boring CC, Squires TS, Tong T. Cancer statistics 1993. CA Cancer J. Clin. 43, 7-26 (1993).
27. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994. CA Cancer J. Clin. 44, 7-26 (1994).
28. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J. Clin. 45, 8-30 (1995).
29. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J. Clin. 46, 5-27 (1996).
30. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J. Clin. 47, 5-27 (1997).
31. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J. Clin. 48, 6-29 (1998).
32. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J. Clin. 49, 8-31 (1999).
33. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J. Clin. 50, 7-33 (2000).
34. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J. Clin. 51, 15-36 (2001).
35. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J. Clin. 52, 23-47 (2002).
36. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J. Clin. 53, 5-26 (2003).
37. Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin. 54, 8-29 (2004).
38. Jemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J. Clin. 55, 10-30 (2005).
39. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J. Clin. 56, 106-130 (2006).
40. Kosary CL. Cancer of the thyroid. In: SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Homer M-J (Eds). National Cancer Institute, SEER Program, Bethesda, MD, USA 217-226 (2007).
41. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin. Diagn. Pathol. 22, 3-32 (2005).
42. Hatami M, Breining D, Owers RL, Del Priore G, Goldberg GL. Malignant struma ovarii - a case report and review of the literature. Gynecol. Obstet. Invest. 65, 104-107 (2008).
43. Deshpande V, Venkatesh SG. Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. Biochim. Biophys. Acta 1430, 157-178 (1999).
44. van de Graaf SAR, Ris-Stalpers C, Pauws E, Mendive FM, Targovnik HM, de Vijlder JJM. Up to date with human thyroglobulin. J. Endocrinol. 170, 307-321 (2001).
45. Rasmussen LB, Ovesen L, Bülow I et al. Relations between various measures of iodine intake and thyroid volume, thyroid nodularity, and serum thyroglobulin. Am. J. Clin. Nutr. 76, 1069-1076 (2002).
46. van Herle AJ, Uller RP. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. J. Clin. Invest. 56, 272-277 (1975).
47. Gerfo PL, Colacchio T, Colacchio D, Feind C. Thyroglobulin in benign and malignant thyroid disease. J. Am. Med. Assoc. 241, 923-924 (1979).
48. Hay ID, Thompson GB, Grant CS et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26, 870-885 (2002).
49. Chow S-M, Law SCK, Au S-K et al. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. Clin. Oncol. 15, 329-336 (2003).
50. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140, 1000-1005 (2006).
51. Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. J. Am. Med. Assoc. 214, 1437-1442 (1970).
52. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 56, 171-196 (1977).
53. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Clin. Endocrinol. Metab. 89, 3668-3676 (2004).
54. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J. Surg. Oncol. 94, 692-700 (2006).
55. Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J. HK Coll. Radiol. 8, 127-135 (2005).
56. 131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J. Nucl. Med. 42, 1470-1475 (2001).
57. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab. 87, 1490-1498 (2002).
58. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 12, 37-43 (2002).
59. 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 60-63 (2006).
60. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787-803 (2006).
61. Cooper DS, Doherty GM, Haugen BR et al. Management guideline for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109-140 (2006).
62. 131)I activities versus untreated patients. J. Clin. Endocrinol. Metab. 86, 4092-4097 (2001).
63. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J. Clin. Endocrinol. Metab. 88, 1107-1111 (2003).
64. Torlontano M, Attard M, Crocetti U et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J. Clin. Endocrinol. Metab. 89, 3402-3407 (2004).
65. 131)I ablation therapy in patients with differentiated thyroid cancer. J. Nucl. Med. 45, 988-994 (2004).
66. Pilli T, Brianzoni E, Capoccetti F et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92, 3542-3546 (2007).
67. Mazzaferri EL, Robbins RJ, Spencer CA et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 88, 1433-1441 (2003).
68. Baloch Z, Carayon P, Conte-Devolx B et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13, 3-126 (2003).
69. Feldt-Rasmussen U, Bech K, Date J. Serum thyroglobulin in patients with toxic and non-toxic goitres compared with sex- and age-matched control subjects. Acta Endocrinol. (Copenhagen) 91, 264-270 (1979).
70. 131I and antithyroid drugs. Clin. Endocrinol. 11, 585-594 (1979).
71. Spencer CA, Fatemi S. Thyroglobulin measurements in thyroid cancer evaluation and surveillance. In: Thyroid Neoplasms. BR Haugen (Ed.). Elsevier, Amsterdam, Holland; Boston, USA 83-105 (2005).
72. Jensen E, Petersen PH, Blaabjerg O, Hegedus L. Biological variation of thyroid autoantibodies and thyroglobulin. Clin. Chem. Lab. Med. 45, 1058-1064 (2007).
73. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 4(4), 223-233 (2008).
74. Gao Y, Yuan Z, Yu Y, Lu H. Mutual interference between serum thyroglobulin and anti-thyroglobulin antibody in an automated chemiluminescent immunoassay. Clin. Biochem. 40, 735-738 (2007).
75. Spencer CA, Takeuchi M, Kazarosyan M et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121-1127 (1998).
76. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90, 5566-5575 (2005).
77. Okosieme OE, Evans C, Moss L, Parkes AB, Premawardhana LD, Lazarus JH. Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin. Chem. 51, 729-734 (2005).
78. Rosário PWS, Maia FFR, Fagundes TA, Vasconcelos FP, Cardoso LD, Purisch S. Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq. Bras. Endocrinol. Metabol. 48, 487-492 (2004).
79. Gorges R, Maniecki M, Jentzen W et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur. J. Endocrinol. 153, 49-55 (2005).
80. Chung JK, Park YJ, Kim TY et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin. Endocrinol. 57, 215-221 (2002).
81. Heemstra KA, Liu YY, Stokkel M et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin. Endocrinol. 66, 58-64 (2007).
82. Aras G, Gultekin SS, Kucuk NO, Genc Y. Is thyroglobulin the stronger indicator for progressive disease than the other conventional factors in same age patient groups with differentiated thyroid cancer? Nucl. Med. Commun. 28, 907-913 (2007).
83. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin. Chem. 42, 661-663 (1996).
84. Weightman DR, Mallick UK, Fenwick JD, Perros P. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer 98, 41-47 (2003).
85. Marquet PY, Daver A, Sapin R et al. Highly sensitive immunoradiometric assay for serum thyroglobulin with minimal interference from autoantibodies. Clin. Chem. 42, 258-262 (1996).
86. Ratcliffe JG, Ayoub LA, Pearson D. The measurement of serum thyroglobulin in the presence of thyroglobulin antibodies. Clin. Endocrinol. 15, 507-518 (1981).
87. Hoofnagle AN, Werner MH. Serum thyroglobulin: a model of immunoassay imperfection. Clin. Lab. Internat. 12, 12-14 (2006).
88. Chinnappa P, Taguba L, Arciaga R et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J. Clin. Endocrinol. Metab. 89, 3705-3709 (2004).
89. Chia SY, Milas M, Reddy SK et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J. Clin. Endocrinol. Metab. 92, 468-475 (2007).
90. Ringel MD. Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. J. Clin. Endocrinol. Metab. 89, 29-32 (2004).
91. Chiovato L, Latrofa F, Braverman LE et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 139, 346-351 (2003).
92. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 88, 3069-3074 (2003).
93. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin. Chem. 42, 164-173 (1996).
94. Antonelli A, Miccoli P, Ferdeghini M et al. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroids 5, 25-28 (1995).
95. Antonelli A, Miccoli P, Fallahi P et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 13, 479-484 (2003).
96. Antonelli A, Miccoli P, Fallahi P et al. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery 140, 1035-1041 (2006).
97. Schlumberger M, Hitzel A, Toubert ME et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J. Clin. Endocrinol. Metab. 92, 2487-2495 (2007).
98. Giovanella L, Ceriani L, Garancini S. High-sensitive 2nd generation thyroglobulin immunoradiometric assay. Clinical application in differentiated thyroid cancer management. Q. J. Nucl. Med. 46, 319-322 (2002).
99. Giovanella L, Ceriani L. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin. Chem. Lab. Med. 40, 480-484 (2002).
100. Zophel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 13, 861-865 (2003).
101. Iervasi A, Iervasi G, Bottoni A et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J. Endocrinol. 182, 287-294 (2004).
102. Giovanella L, Ceriani L, Ghelfo A et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin. Chem. Lab. Med. 44, 648-652 (2006).
103. Smallridge RC, Meek SE, Morgan MA et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J. Clin. Endocrinol. Metab. 92, 82-87 (2007).
104. Iervasi A, Iervasi G, Ferdeghini M et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin. Endocrinol. 67, 434-441 (2007).
105. 4 < 1 ng/ml determined by traditional assays? Clin. Endocrinol. 68, 338-342 (2008).
106. Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 14, 959-963 (2004).
107. Uruno T, Miyauchi A, Shimizu K et al. Usefulness of chyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J. Surg. 29, 483-485 (2005).
108. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J. Clin. Endocrinol. Metab. 91, 1364-1369 (2006).
109. Snozek CL, Chambers EP, Reading CC et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J. Clin. Endocrinol. Metab. 92, 4278-4281 (2007).
110. Cunha N, Rodrigues F, Curado F et al. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur. J. Endocrinol. 157, 101-107 (2007).
111. Orija IB, Hamrahian AH, Reddy SS. Management of nondiagnostic thyroid fine-needle aspiration biopsy: survey of endocrinologists. Endocr. Pract. 10, 317-323 (2004).
112. Florentine BD, Staymates B, Rabadi M, Barstis J, Black A. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer 107, 406-416 (2006).
113. Bore AL, Boizel R, Faure P et al. Significance of low levels of thyroglobulin in fine needle aspirates from cervical lymph nodes of patients with a history of differentiated thyroid cancer. Eur. J. Endocrinol. 158, 691-698 (2008).
114. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin. Endocrinol. 62, 156-162 (2005).
115. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. J. Am. Med. Assoc. 295, 2164-2167 (2006).
116. McDougall IR, Hay ID. ATA Guidelines: do patients with stage I thyroid cancer benefit from (131). Thyroid 17, 595-596 (2007).
117. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56, 531-538. (1985).
118. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer 71, 4022-4029 (1993).
119. Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathol. 23, 319-325 (2007).
120. Bhattacharyya N, Fried MP. Assessment of the morbidity and complications of total thyroidectomy. Arch. Otolaryngol. Head Neck Surg. 128, 389-392 (2002).
121. Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery 133, 180-185 (2003).
122. Rosato L, Avenia N, Bernante P et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J. Surg. 28, 271-276 (2004).
123. Stojadinovic A, Henry LR, Howard RS et al. Prospective trial of voice outcomes after thyroidectomy: evaluation of patient-reported and clinician-determined voice assessments in identifying post thyroidectomy dysphonia. Surgery 143, 732-742 (2008).
124. Spear SA, Theler J, Sorensen DM. Complications after the surgical treatment of malignant thyroid disease. Mil. Med. 173, 399-402 (2008).
125. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J. Nucl. Med. 39, 1551-1554 (1998).
126. Zettinig G, Hanselmayer G, Fueger BJ et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur. J. Nucl. Med. Mol. Imag. 29, 1428-1432 (2002).
127. Mandel SJ, Mandel M. Radioactive iodine and the salivary glands. Thyroid 13, 265-271 (2003).
128. Hyer S, Konga A, Pratta B, Harmera C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin. Oncol. 19, 83-86 (2007).
129. Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther. Onkol. 168, 337-343 (1992).
130. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J. Nucl. Med. 36, 21-27 (1995).
131. de Vathaire F, Schlumberger M, Delisle MJ et al. Leukaemias end cancers following iodine-131 administration for thyroid cancer. Br. J. Cancer 75, 734-739 (1997).
132. Sandeep TC, Strachan MW, Reynolds RM et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J. Clin. Endocrinol. Metab. 91, 1819-1825 (2006).
133. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 93, 504-515 (2008).
134. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
135. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat. Clin. Pract. Oncol. 3, 621-632 (2006).
136. Gloeckler Ries LA, Eisner MP. Cancer of the female breast. In: SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Gloeckler Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (Eds). National Cancer Institute, SEER Program, Bethesda, MD, USA 101-110 (2007).